Would you consider offering adjuvant chemotherapy to a patient with HR+, Her2- T1c disease with negative axillary lymph nodes, but with a positive intramammary node?
Intramammary lymph node involvement has been shown to have a poorer prognosis (Hogan, Surg Onc, 2010). Would Oncotype be useful in these patients?
Answer from: Medical Oncologist at Academic Institution
Yes, I would consider adjuvant chemotherapy for this node-positive breast cancer.
Yes, the emerging evidence is suggestive that Oncotype DX is as useful in node-positive as in node-negative breast cancer for determination of prognosis and probably decisions regarding indications for chemotherapy.
...